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Abstract Rapid antimicrobial susceptibility testing (AST) is
essential for early and appropriate therapy. Methods with short
detection time enabling same-day treatment optimisation are
highly favourable. In this study, we evaluated the potential of a
digital time-lapse microscope system, the oCelloScope sys-
tem, to perform rapid AST. The oCelloScope system demon-
strated a very high accuracy (96 % overall agreement) when
determining the resistance profiles of four reference strains,
nine clinical isolates, including multi-drug-resistant isolates,
and three positive blood cultures. ASTof clinical isolates (168
antimicrobial agent–organism combinations) demonstrated
3.6 % minor, no major and 1.2 % very major errors of the
oCelloScope system compared to conventional susceptibility
testing, as well as a rapid and correct phenotypic detection of
strains with methicillin-resistant Staphylococcus aureus
(MRSA) and extended-spectrum β-lactamase (ESBL) pro-
files. The net average time-to-result was 108 min, with 95 %
of the results being available within 180 min. In conclusion,
this study strongly indicates that the oCelloScope system
holds considerable potential as an accurate and sensitive
AST method with short time-to-result, enabling same-day
targeted antimicrobial therapy, facilitating antibiotic steward-
ship and better patient management. A full-scale validation of
the oCelloScope system including more isolates is necessary
to assess the impact of using it for AST.
Introduction
Bacterial multidrug resistance is emerging worldwide at an
alarming rate and is now recognised as a major public health
threat [1]. This crisis is not likely to be solved by new antibi-
otics due to the low rate of antibiotic discovery and by the
probability that pathogens will continue to evolve resistance to
antibiotics. The initiation of effective antibiotic therapy early
in the course of an infection may reduce the probability of
pathogens evolving resistance [2]. Especially in the case of
sepsis and bloodstream infections, early appropriate antimi-
crobial therapy is important to decrease mortality [3]. Sepsis
management includes empirical antimicrobial therapy started
as soon as possible without awaiting results from antimicro-
bial susceptibility testing (AST) [4, 5]. As empirical antimi-
crobial therapy is mainly composed of broad-spectrum antibi-
otics, this can perpetuate the cycle of increasing resistance [6].
Consequently, early determination of antimicrobial suscepti-
bility is pivotal in targeted antimicrobial therapy in order to
combat the escalating rates of resistance, as well as to decrease
mortality.
Today, AST in routine clinical microbiology laboratories is
generally performed by conventional methods such as disc
diffusion, broth dilution or Etest [7, 8]. During the last decade,
several technologies have been suggested as candidates for
more accurate AST, e.g. whole-genome sequencing, mass
spectrometry, fluorescence-activated cell sorting and microar-
rays [7]. Technologies relying on genotypic and proteomic
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analysis of resistance determinants such as whole-genome se-
quencing, polymerase chain reaction (PCR) andmatrix-assisted
laser desorption/ionisation time-of-flight (MALDI-TOF) have
the key limitation in that they are unable to detect novel resis-
tance mechanisms [9, 10]. In addition, some of these new tech-
niques are time-consuming and characterised by expensive in-
struments, high analysis costs, the need for specialised technical
personnel and are, in some cases, limited by single-sample
analysis. Automated instruments such as Vitek 2
(bioMérieux), Phoenix 100 (BD Biosciences) and MicroScan
WalkAway (Siemens) are commonly used methods for AST as
they are easy to operate and reduce the time-to-result [11–14].
Nevertheless, in clinical practice, even faster AST methods are
required if effective treatment with targeted antibiotic is to be
achieved within the same working day.
In a previous study, we demonstrated the oCelloScope sys-
tem to be a fast and sensitive, high-throughput AST method
capable of detecting antibiotic susceptibility within 6 min for
Escherichia coli and within 30 min in complex urine samples
from pigs suffering from urinary tract infections [15]. In this
study, we performed a preliminary evaluation of the ability of
the oCelloScope system to analyse antimicrobial resistance by
monitoring bacterial cell growth. The accuracy of the
oCelloScope system was examined together with the time
required for AST. This initial screening constitutes the proof




Four quality control (QC) reference strains were included to
validate the antimicrobial susceptibility results obtained by the
oCelloScope system: Escherichia coli ATCC 25922,
Staphylococcus aureus ATCC 29213, Enterococcus faecalis
ATCC 29212 and Streptococcus pneumoniae ATCC 49619.
The QC reference strains used are recommended for quality
control by the Clinical and Laboratory Standards Institute
(CLSI) and the European Committee on Antimicrobial
Susceptibility Testing (EUCAST). In addition, nine clinical
isolates, collected in Denmark during the period 2008–
20012, were included: two S. epidermidis [one oxacillin resis-
tant (mecA-positive) and one oxacillin and penicillin suscep-
tible], one S. pneumoniae (penicillin intermediate and
trimethoprim/sulphamethoxazole resistant), two S. aureus
[one methicillin-resistant S. aureus (MRSA) (mecA-positive)
and one methicillin-susceptible S. aureus (MSSA)], two
E. faecalis [both gentamicin high-level resistant and one van-
comycin resistant (vanB-positive)] and two E. coli [one
extended-spectrum β-lactamase (ESBL) and one resistant to
ampicillin, gentamicin and ciprofloxacin].
Blood culture instrumentation and media
Blood samples from patients (8–10 mL/patient) with suspected
bacteraemia were collected in standard aerobe non-charcoal
BacT/ALERT FA blood culture bottles (bioMérieux, Marcy-
l’Etoile, France) and handled according to the manufacturer’s
instructions. Blood culture bottles were incubated in the BacT/
ALERT 3D system (bioMérieux, Marcy-l’Etoile, France) at
Aarhus University Hospital (Aarhus, Denmark). Blood cultures
detected as positive by the BacT/ALERT 3D system were
Gram stained and examined for bacterial morphology by light
microscopy. All blood cultures used in this study were
recognised as positive during the night and not processed until
8 o’clock the following morning. Species identification of iso-
lates by the clinical laboratory was provided after the comple-
tion of oCelloScope AST measurements. Consequently, only
preliminary phenotypic characterisation including Gram stain-
ing and examination of cellular morphology by light microsco-
py was provided prior to oCelloScope AST.
Antimicrobial susceptibility testing by manually
interpreted Sensititre® plates
AST was performed on all bacterial isolates using the
Sensititre® system (TREK Diagnostic Systems, Cleveland,
OH, USA), according to the manufacturer’s instructions.
Three different Sensititre® plates were used: NF: E. coli,
GPALLIF: Staphylococci and Enterococci, and STP6F:
S. pneumoniae. Bacterial isolates were grown overnight on
5 % horse blood agar (Statens Serum Institut, Copenhagen,
Denmark). Colony material was emulsified in sterile water
(E. coli, Staphylococcus spp. and Enterococcus spp.) or
Sensititre® cation-adjusted Mueller–Hinton broth with TES
(CAMHBT, TREK Diagnostic Systems (S. pneumoniae) and
the suspension was adjusted to 0.5 McFarland standard using
the Vitek DensiChek densitometer (bioMérieux). For
Staphylococcus spp., Enterococcus spp. and E. coli, 10 μL
was transferred into 11 mL CAMHBT and 50 μL of the sus-
pension was inoculated into each well on the Sensititre® plate.
For S. pneumoniae, 100 μL was transferred into 11 mL
Sensititre® cation-adjusted Mueller–Hinton broth with TES
and lysed horse blood (CAMHBT+LHB, TREK Diagnostic
Systems) and 100 μL of the suspension was inoculated into
each well on the Sensititre® plate. Plates were incubated for
20–24 h at 35 °C. For each test, we performed an inoculum
check according to the manufacturer’s instructions. AST re-
sults were read using the Sensititre® Manual viewer.
Antimicrobial susceptibility testing by the oCelloScope
system
QC reference strains and clinical isolates were grown under
atmospheric conditions at 37 °C in CAMHBT, except
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S. pneumoniae, which was grown in CAMHBT+LHB. All
isolates were grown overnight and transferred to new tubes
and incubated for 2 h before AST. Positive blood cultures
were prepared by centrifugation at 200×g for 5 min (Sigma
3-18 k, 12171 rotor, Buch & Holm, Herlev, Denmark) to re-
move human blood cells, followed by resuspension of the
bacterial pellet in CAMHBT. All broth–bacteria suspensions
were diluted to McFarland 0.5 based on OD600 measurements
using a UV-3100 PC Spectrophotometer (VWR, Herlev,
Denmark) and subsequently diluted in cation-adjusted
Mueller–Hinton broth to a final bacterial cell suspension of
approximately 1×105 bacteria/mL for all bacteria except for
S. pneumoniae, which was diluted to a final concentration of
approximately 5×105 bacteria/mL. To facilitate focus adjust-
ment of the oCelloScope system, beads were added to bacte-
rial cell suspensions (2×104 6-μm beads/mL, microsphere
standard, B7277, Invitrogen, Naerum, Denmark). Broth–bac-
teria–bead suspensions were added to Sensititre® plates
(TREK Diagnostic Systems). NF, GPALL1F and STP6F
plates were used as specified above. Bacterial cell suspensions
were carefully transferred from the round-bottomed
Sensititre® plates to flat-bottomed Nunc Edge 96-well plates
(Thermo Fisher Scientific, Roskilde, Denmark) in order to be
analysed by the oCelloScope system, as it cannot analyse
round-bottomed plates. The determination of minimum inhib-
itory concentration (MIC) values for all experiments on QC
reference strains and clinical isolates was carried out in tripli-
cate experiments. The results were reported when at least two
out of three MIC results were in agreement.
The oCelloScope is a digital time-lapse microscopy technol-
ogy that scans through a fluid sample generating series of im-
ages as described in 2013 by Fredborg et al.[15]. As a result of
the tilted imaging plane, the images recorded by the
oCelloScope system constitute a parallelepipedum that forms
the image stack. The projected z-stack image of a single z-plane
was generated by combining the tilted images. Prior to image
acquisition, setting the focus manually was performed for each
of the 96 wells, taking 10–15 min. Image acquisition was per-
formed in one scan area in the centre of each well covering
approximately 40 % of the well, which was scanned repeatedly
every 15 min for 12 h. Figure 1a shows one image plane
recorded for the E. coli QC reference strains used for the eval-
uation of the oCelloScope system. The oCelloScope instrument
was placed inside an Innova 44 incubator (New Brunswick
Scientific), allowing precise temperature regulation.
Time-lapse experiments, digital analysis and image pro-
cessing were conducted by a custom automation script in
MATLAB [MATLAB v 8.0.0.783 (R2012b), The
MathWorks Inc., Natick, MA, USA, 2000]. Growth kinetics
were determined by image stack processing based on contrast-
based segmentation and extraction of surface area (SESA).
Data analysis
Bacterial susceptibility data for the QC reference strains obtain-
ed by the oCelloScope system were compared to QC ranges
reported by TREK Diagnostic Systems (version 2.0). The
TREK QC ranges were identical to the ranges given by the
CLSI (M100-S23, 2013), with penicillin against S. aureus
ATCC 29213 being the only outlier (Table 1). For clinical and
blood culture isolates, antimicrobial susceptibility data
obtained by the oCelloScope system were compared to
manually read Sensititre® plates. The results from man-
ually read Sensititre® plates were regarded as the gold
standard. The time-to-result was measured from when the
oCelloScope initiated image recording; the bacterial inoculum
had been in contact with antimicrobials for approximately
10 min at this time point.
Essential agreement was defined as MIC agreement within
+/− one log2. All clinical isolates were classified as S (suscep-
tible), I (intermediate) or R (resistant) according to the CLSI
breakpoints (M100-S23, 2013). Categorical agreement was de-
fined as agreement within the S-I-R classification. Minor errors
were defined as susceptible or resistant isolates misclassified as
intermediate or intermediate isolates misclassified as resistant
or susceptible, major errors were defined as susceptible isolates
misclassified as resistant and very major errors were defined as
resistant isolates misclassified as susceptible.
GraphPad Prism version 6.00 for Windows (GraphPad
Software, San Diego, CA, USA) was used for data and statis-
tical analysis, as well as graphing.
Fig. 1 Example of an oCelloScope image and graphical output. a
Growth curves for S. aureus ATCC29213 treated with vancomycin
(0.25–32 mg/L) and without as a positive control (POS CON). b 2D
picture of S. aureus ATCC29213 obtained by the oCelloScope system,
with a magnitude comparable to a200× magnification in a standard light
microscope
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Results
Antimicrobial susceptibility testing of quality control (QC)
reference strains
The ability of the oCelloScope system to determine antibiotic
susceptibility was assessed by testing four QC reference
strains, E. coli ATCC25922, S. aureus ATCC29213,
S. pneumoniae ATCC49619 and E. faecalis ATCC29212,
using the Sensititre® microdilution plates. Figure 1 shows
the image output (a) and growth curves (b) determined by
the oCelloScope system for S. aureus ATCC29213.
Agreements and discrepancies between MIC values obtained
by the oCelloScope system and target QC ranges given by
TREK Diagnostic Systems are presented in Table 1. Due to
the concentration ranges of the antimicrobial panels, it was not
possible to determine an exact MIC value for some antimicro-
bials (e.g. cefotaxime, tetracycline and trimethoprim/
sulphamethoxazole). These values are given as≤than the low-
est concentration in the panel range (all wells without growth)
Table 1 Correlation between the oCelloScope system and TREK QC ranges for antimicrobial susceptibility of QC reference strains
Antimicrobial susceptibility expressed as MIC values: oCelloScope value (TREK Diagnostic Systems QC range)
Antimicrobial agent E. coli ATCC25922 S. pneumoniae ATCC 49619 S. aureus ATCC 29213 E. faecalis ATCC 29212
Amikacin 2 (0.5–4) – – –
Ampicillin – – – 1 (0.5–1)
Ampicillin/sulbactam 2:1 ratio 4/2 (2/1–8/4) – – –
Aztreonam ≤0.12 (0.06–0.25) – – –
Ceftazidime 0.25 (0.06–0.5) – – –
Cefoperazone ≤0.25 (0.12–0.5) – – –
Cefoxitin screen – – ≤6 (≤6) –
Cefotaxime ≤0.25 (0.03–0.12) ≤0.25 (0.03–0.12) – –
Ceftazidime 0.25 (0.06–0.5) – – –
Ceftriaxone ≤0.25 (0.03–0.12) ≤0.06 (0.03–0.12) – –
Chloramphenicol 4 (2–8) 1 (2–8) 8 (2–16) 4 (4–16)
Ciprofloxacin ≤0.06 (0.004–0.015) – ≤0.25 (0.12–0.5) 0.5 (0.25–2)
Clindamycin – 0.25 (0.03–0.12) ≤0.12 (0.06–0.25) >2 (4–16)
Daptomycin – 0.06 (0.06–0.5) 0.5 (0.12–1) 2 (1–4)
Erythromycin – ≤0.12 (0.03–0.12) 0.25 (0.25–1) 1 (1–4)
Gentamicin 1 (0.25–1) – ≤0.5 (0.12–1) –
Imipenem 0.12 (0.06–0.25) – – –
Levofloxacin 0.03 (0.008–0.06) 0.5 (0.5–2) 0.25 (0.06–0.5) 1 (0.25–2)
Linezolid – 0.25 (0.25–2) 2 (1–4) 2 (1–4)
Moxifloxacin – ≤0.5 (0.06–0.25) ≤0.06 (0.015–0.12) 0.12 (0.06–0.5)
Nitrofurantoin – – 16 (8–32) 16 (4–16)
Oxacillin – – 0.25 (0.12–0.5) >4 (8–32)
Penicillin – 0.25 (0.25–1) 0.25* (0.12–1) 2 (1–4)
Piperacillin 2 (1–4) – – –
Piperacillin/tazobactam 4 2/4 (1/4–4/4) – – –
Quinupristin/dalfopristin – – 0.25 (0.25–1) 2 (2–8)
Rifampin – – ≤0.12 (0.004–0.015) 0.5 (0.5–4)
Tetracycline 2 (0.5–2) ≤0.5 (0.06–0.5) ≤0.5 (0.12–1) 16 (8–32)
Ticarcillin 16 (4–16) – – –
Ticarcillin/clavulanic acid 2 8/2 (4/2–16/2) – – –
Tigecycline – 0.06 (0.015–0.12) 0.06 (0.03–0.25) 0.12 (0.03–0.12)
Tobramycin 1 (0.25–1) – – –
Trimethoprim/sulphamethoxazole 0.12/2.38 (≤0.5/9.5) ≤0.25/4.75 (0.12/2.4–1/19) ≤0.12/2.38 (≤0.5/9.5) ≤0.12/2.38 (≤0.5/9.5)
Vancomycin – ≤0.25 (0.12–0.5) 1 (1–4) 2 (1–4)
–: the antimicrobial is not present on the TREK Sensititre® plates chosen for AST. ≤: MIC value is below the range tested. >: MIC value is above the
range tested. *: MIC value is different from those recommended in CLSI M100
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or>than the highest concentration in the panel range (growth
in all wells). A total of 72 bacteria–antibiotic combinations
were analysed, resulting in 97 % agreement between the re-
sults obtained by the oCelloScope system and the TREK tar-
get QC range. Similar results were obtained in three separate
identical experiments. The average time-to-result for QC ref-
erence strains by the oCelloScope system was 102 min, with
93 % of the results being available within 180 min (Table 2).
Two discrepancies of the 72 bacteria–antibiotic combinations
were observed: S. pneumoniae tested against chloramphenicol
and clindamycin (Table 1). For chloramphenicol, the MIC
value measured by the oCelloScope system was one log2 con-
centration lower than the QC range, whereas the MIC value
for clindamycin was one log2 concentration higher than the
QC range.
Antimicrobial susceptibility testing of clinical isolates
Nine clinical isolates representing five different bacterial spe-
cies with distinctive resistance profiles were included in this
study (see the section on the experimental procedures for fur-
ther information). A total of 168 bacteria–antibiotic combina-
tions were tested using the Sensititre® microdilution plates.
MIC values obtained by the oCelloScope system were com-
pared to MIC values obtained by manual reading of
Sensititre® plates. The average time-to-result for bacterial iso-
lates by the oCelloScope system was 100 min, with 95 % of
the results being available≤180 min (Table 2). The average
essential and categorical agreement was 93 % (156 of 168)
and 93 % (136 of 146), respectively. Bacteria–antibiotic com-
binations that were not in agreement with conventional
methods are listed in Table 3. Two major errors (1.2 %) were
observed: S. epidermidis tested against nitrofurantoin and
E. coli tested against chloramphenicol. Five minor errors
(3.6 %) were observed: one for S. pneumoniae and four for
E. faecalis, where two isolates were classified as rifampicin
susceptible, one isolate was classified as linezolid intermedi-
ate, one isolate was classified as vancomycin intermediate and
one isolate was classified as erythromycin intermediate. There
were no major errors for any of the clinical isolates.
Strains with MRSA and ESBL resistance profiles were
detected correctly by the oCelloScope system. The
vancomycin-resistant enterococci (VRE) strain was detected
with a minor error regarding vancomycin: oCelloScope
MIC=8 mg/L vs. Sensititre® MIC >32 mg/L.
Antimicrobial susceptibility testing on positive blood
cultures
To evaluate the ability of the oCelloScope system to perform
AST, three positive blood cultures were included. The selec-
tion of appropriate antimicrobial Sensititre® panels and
growth media was based on morphology and Gram staining.
Species identification of the bacteria was performed at Aarhus
University Hospital and the results were not available prior to
AST by the oCelloScope system. Table 4 shows the AST
results obtained by the oCelloScope system compared to sus-
ceptibility results obtained by testing the positive blood cul-
tures with the manual Sensititre® system. The average time-
to-result for susceptibility testing by the oCelloScope system
ranged from 1 to 4.2 h, depending on the bacteria–antibiotic
combination and whether the bacteria had reached stationary
Table 2 Time-to-result in
minutes required for the
oCelloScope system to gain AST
results for four QC (ATCC)
strains, nine clinical isolates and
three positive blood cultures (BC)
Strain av. time 25th percentile 75th percentile min max
S. aureus ATCC 118 53 143 30 360
E. coli ATCC 93 49 120 30 180
E. faecalis ATCC 112 68 143 45 270
S. pneumoniae ATCC 84 60 90 30 165
S. aureus MRSA 75 30 90 30 240
S. aureus MSSA 86 45 120 45 180
S. epidermidis Pen-R 103 60 120 30 240
S. epidermidis Pen-S 92 60 120 30 180
S. pneumoniae 91 60 90 45 180
E. coli ESBL 113 60 155 45 300
E. coli Amp-R 117 60 120 30 390
E. faecalis VRE 130 60 120 30 600
E. faecalis Gen-R 94 45 180 30 180
S. aureus BC 248 230 230 230 450
E. coli BC 109 90 120 45 280
E. faecalis BC 62 45 75 30 105
Results are expressed as average time (av. time), 25th percentile, 75th percentile, minimum time-to-result (min)
and maximum time-to-result (max)
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growth phase prior to testing (Table 2). The overall essential
agreement was 95% (57 of 60). Two of the discrepancies were
S. aureus tested against ampicillin (oCelloScope MIC=1 mg/
L vs. Sensititre® MIC=4 mg/L) and S. aureus tested against
penicillin (oCelloScope MIC=0.5 mg/L vs. Sensititre®
MIC=4mg/L). Bothmethods categorised the S. aureus isolate
as resistant to penicillin. The third discrepancy was observed
for E. coli tested against chloramphenicol (oCelloScope MIC
8mg/L vs. Sensititre®MIC>16mg/L). The categorical agree-
ment was 100 % for S. aureus and E. faecalis.
Discussion
In this study, we performed an initial screening to evaluate the
potential of the oCelloScope system to perform rapid AST.
This initial screening constitutes proof-of-concept in relation
to bloodstream infections and, although this is not a full val-
idation of the oCelloScope system, the results are compared to
commercially available systems.
Four QC reference strains were used to evaluate the ability
of the oCelloScope system for susceptibility determination, as
directed by standards for the assessment of antimicrobial sus-
ceptibility [16, 17], with 95 % of the results lying within the
QC target range. Subsequently, the evaluationwas extended to
include 168 bacteria–antibiotic combinations of common
blood culture pathogens with different resistance profiles,
resulting in an overall agreement of 96 %. It has been reported
that an overall error rate of <10 % should be obtainable for an
accepted performance of susceptibility testing [18–20].
According to guidelines, categorical agreements should be
>90 %, major errors should be <3 % and very major errors
should be<1.5 % [21]. In this study, the AST results of bacte-
ria–antibiotic combinations with CLSI defined breakpoints
showed categorical agreement for 93 %, 1.2 % very major
errors and no major errors when determined by the
oCelloScope system.
The AST results obtained in the two multidrug-resistant
organisms, an MRSA and an ESBL-producing E. coli,
showed no discrepancies in categorical agreement.
Evaluation of the Vitek 2 and Phoenix systems for AST on
blood cultures demonstrated categorical agreement rates of
94.6 % for Vitek 2 and 100 % for Phoenix when analysing
20 methicillin-resistant staphylococci tested against five anti-
microbial agents [13]. Categorical agreements for 23 ESBL-
positive E. coli tested against three antimicrobial agents were
97.5 % and 98.1 % for Vitek 2 and Phoenix, respectively [13].
For the VRE strain, oCelloScope determined it as intermedi-
ate, while manual reading classified it as resistant to vanco-
mycin. The VRE strain carried the vanB gene. The vanB ge-
notype usually has a vancomycin MIC distribution in the
range 8–32 mg/L and generally confers lower MIC to vanco-
mycin than the vanA genotype (typical vancomycin MIC>
64 mg/L) [22]. Rapid detection of the vanB genotype has
proven to be difficult in automated systems and has led to
the development of optimised panels [23, 24]. The disc diffu-
sion test, agar screen and Etest showed 93 %, 100 % and
100 % sensitivity for detecting the vanB genotype, respective-
ly, although agar diffusion tests can be challenging, as they
require careful assessment of zone edges (eucast.org, CLSI
M100 [23]. Thus, a full validation of the oCelloScope system
should include a panel of multidrug-resistant species to deter-
mine its potential to rapidly determine the resistance profiles
of such strains.
VME were observed with nitrofurantoin for S. epidermidis
and with chloramphenicol for E. coli, both categorised as sus-
ceptible by the oCelloScope system. In a previous study eval-
uating Vitek 2, essential agreements with nitrofurantoin were
93.7 % for staphylococci and 88.9 % for enterococci [25],
indicating that susceptibility testing for nitrofurantoin may
Table 3 AST of nine clinical isolates by the oCelloScope system and compared to the manually read Sensititre® system (gold standard)






Categorical agreement (S-I-R according to CLSI breakpoints)
% Minor errors Major errors Very major errors
S. epidermidis 19 (17) 90 97 0 0 1a
S.pneumoniae 20 (18) 85 94 1b 0 0
S. aureus 19 (17) 100 100 0 0 0
E. faecalis 15 (11) 83 78 5c 0 0
E. coli 22 (19) 100 98 0 0 1d
Results are expressed as essential agreements ±1 log2 and categorical agreements according to CLSI breakpoints
a S. epidermidis: one isolate classified as nitrofurantoin susceptible
b S. pneumoniae: one isolate classified as penicillin susceptible
cE. faecalis: two isolates classified as rifampicin susceptible, one isolate classified as linezolid intermediate, one isolate classified as vancomycin
intermediate and one isolate classified as erythromycin intermediate
dE. coli: one isolate classified as chloramphenicol susceptible
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be difficult for automated instruments. A minor error was
observed for E. faecalis when tested against linezolid.
Manual reading classified the isolate as susceptible (MIC
values ≤1 mg/L and 2 mg/L), while the oCelloScope system
classified both isolates as intermediate (MIC=4 mg/L for both
isolates). This discrepancy may be explained by the fact that
linezolid MIC is determined at 80–90 % inhibition of growth
(i.e. visible growth in negative wells) for manual reading,
while the oCelloScope system measured MIC at 100 % inhi-
bition of growth. The oCelloScope software, however, can be
adjusted to allow for 10–20 % growth. For all other discrep-
ancies, measurements performed by the oCelloScope system
resulted in lower MIC values than the manually read
Sensititre® plates, which were expected, since rapid AST
methods generally result in lower MIC values.
Based on the promising results from analysis of the clinical
isolates, the ability of the oCelloScope system to analyse pos-
itive blood cultures was examined. Only one discrepancy was
observed in the 60 bacteria–antibiotic combinations: E. coli
against chloramphenicol. Two possible sources of errors in
Table 4 Results of AST of
positive blood cultures. Positive
blood cultures analysed with the
oCelloScope system compared to
MIC values obtained by testing
the blood culture isolates with the
manually read Sensititre® system
oCelloScope MIC value (Sensititre® MIC value)
Antimicrobial agent E. coli S. aureus E. faecalis
Amikacin ≤4 (≤4) – –
Ampicillin – 1 (4) 1 (1)
Ampicillin/sulbactam 2:1 ratio ≤2/1 (≤2/1) – –
Aztreonam ≤2 (≤2) – –
Carbenicillin ≤32 (≤32) – –
Ceftazidime ≤1 (≤1) – –
Cefepime ≤2 (≤2) – –
Cefoperazone ≤4 (≤4) – –
Cefotaxime ≤4 (≤4) – –
Ceftriaxone ≤4 (≤4) – –
Chloramphenicol 16 (8) 4 (8) 8 (8)
Ciprofloxacin ≤0.25 (≤0.25) ≤1 (≤1) ≤1 (≤1)
Clindamycin – ≤0.5 (≤0.5) >2 (>2)
Daptomycin – ≤0.5 (≤0.5) 1 (1)
Erythromycin – ≤0.25 (0.5) 2 (2)
Gentamicin ≤1 (≤1) ≤2 (≤2) 16 (16)
Imipenem ≤1 (≤1) – –
Levofloxacin ≤0.12 (≤0.12) ≤0.25 (≤0.25) 1 (1)
Linezolid – ≤1 (2) 2 (2)
Lomefloxacin ≤0.5 (≤0.5) – –
Moxifloxacin – ≤0.25 (≤0.25) ≤0.25 (≤0.25)
Nitrofurantoin – ≤32 (≤32) ≤32 (≤32)
Oxacillin – ≤0.25 (≤0.25) >4 (>4)
Penicillin – 0.5 (4) 8 (4)
Piperacillin ≤8 (≤8) – –
Piperacillin/tazobactam 4 ≤8/4 (≤8/4) – –
Quinupristin/dalfopristin – ≤0.5 (≤0.5) >4 (>4)
Rifampin – ≤0.5 (≤0.5) 2 (2)
Tetracycline ≤1 (≤1) ≤2 (≤2) >16 (>16)
Ticarcillin ≤8 (≤8) – –
Ticarcillin/clavulanic acid 2 ≤16/2 (≤16/2) – –
Tigecycline – 0.12 (0.06) 0.25 (0.12)
Tobramycin ≤1 (≤1) – –
Trimethoprim/sulphamethoxazole ≤0.5/9.5 (≤0.5/9.5) ≤0.5/9.5 (≤0.5/9.5) ≤0.5/9.5 (≤0.5/9.5)
Vancomycin – 1 (1) 2 (2)
–: the antimicrobial was not included on the chosen TREK Sensititre® plate. ≤: MIC value is below the range
tested. >: MIC value is above the range tested
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AST are direct inoculation of mixed cultures and non-
standardised inoculum size [26–28]. In some cases, mixed
blood cultures can be determined by microscopy and Gram
staining and, thus, be excluded from the AST method. If the
blood culture contains bacteria with different morphology, this
would be visible in the oCelloScope system and precautions
may be taken. In order to ensure standardised inoculum size,
all bacterial cell suspensions were adjusted to McFarland 0.5.
Although blood cells and traces of blood culture broth can
interfere with measurements, this would be visible in the
oCelloScope system when setting up the experiment. For
many compounds, the MIC value increases as inoculum in-
creases (e.g. S. aureus tested against ciprofloxacin, oxacillin
and vancomycin), while other antimicrobials such as chloram-
phenicol or the tetracyclines are not associated with inoculum
effects [29, 30]. An advantage of the oCelloScope system, as
well as other growth-based susceptibility tests, is that it only
takes live bacteria into account and that this method, in con-
trast to agar diffusion tests, is independent of the antibiotic
diffusion rate and time to macroscopically visible growth.
Taken together, the results from studies on QC reference
strains, clinical isolates and positive blood cultures showed
an overall high accuracy of the oCelloScope system.
A major aim of this study was to assess whether the
oCelloScope system could reduce the turnaround time of
AST compared to conventional AST methods. If so, the
oCelloScope systemmight serve as an essential screening tool
to accelerate appropriate antibiotic therapy. The benefits of
timely reporting of susceptibility results have been highlighted
previously [31, 32]. Testing of QC reference strains and clin-
ical isolates resulted in an average time-to-result of 100 min,
with MIC determination being possible for 43 % of the bac-
teria–antibiotic combinations within 1 h (Table 2). However, it
is possible to decrease the time-to-result even further by
optimising algorithms and software settings, as the
oCelloScope system was set up to analyse every 15 min for
12 h. Naturally, if the oCelloScope system was set up to ana-
lyse every 5 min, the time-to-result would have been shorter.
Furthermore, a 2-h culture step was included to ensure early to
mid-exponential phase of growth of the bacteria prior to anal-
ysis by the oCelloScope system. In a clinical setting, this step
could be omitted, as the technique of the oCelloScope system
could be integrated into automated blood culturing systems
and, therefore, perform AST directly on positive blood
cultures.
For AST on the included positive blood cultures, the aver-
age time-to-result ranged from 1 to 4.5 h, depending on the
bacteria–antibiotic combination and whether the bacteria had
reached the stationary growth phase. All blood cultures used
in this study became positive during the night and were not
processed until 8 o’clock the following morning.
Consequently, these cultures may have been positive for up
to 13 h. A lag phase of 2 h was observed for the S. aureus
blood culture, which is the major reason for the prolonged
time-to-result compared to that of the QC reference strains
and the clinical isolates. According to the manufacturer’s in-
structions, the incubation time of Sensititre® MIC plates
should be 18 h. This means a reduction in the average time-
to-result of approximately 16.5 h by using the oCelloScope
system. The fastest commercially available automatic AST
method (Vitek 2, bioMeriéux, France) requires approximately
8 h to detect antimicrobial resistances in bacteria [33]. Taken
together, these results strongly indicate that the oCelloScope
system has the potential to decrease the time-to-result for AST.
Translating this into daily workflow entails that same-day
treatment or adjustments of antibiotic therapy are possible
with the oCelloScope system. Only a few methods enable
AST under 1 h, and only one method enables the determina-
tion of a real MIC value; however, this method is currently not
commercially available [7]. AST of blood cultures by
oCelloScope using Sensititre® microdilution plates may be
incorporated into the clinical laboratory workflow, with
95 % of the results being available within 3 h and can be
confirmed by inspection of the movies provided for each of
the 96 wells.
The results from the three different types of samples clearly
show that several parameters influence the time-to-result, in-
cluding bacterial growth phase, bacterial doubling time,
mode-of-action of the antibiotic and bacterial expression of
resistance genes. However, it is clear that the prolonged
time-to-result for the positive blood cultures is due to the
growth state of the bacteria. Large variations of the time-to-
result were observed for all samples, depending on the antibi-
otic of concern. As the number of isolates and species tested
are limited, these variations might evolve when a greater num-
ber are included. However, it is crucial to note that part of
these variations may not be clinically relevant, due to, for
example, the site of infection, expression of resistance genes
or antibiotic preference.
To take full advantages of the oCelloScope technique in a
clinical setting, it should be incorporated into a fully automatic
system, such as the blood culture system, or further developed
into a fully automatic AST system of its own, and, most im-
portantly, be able to analyse the bacterial infection as early as
possible. However, considering the current version of the
oCelloScope system, analysing a 96-well plate of growth-
optimised bacteria using autofocus, continuing image acqui-
sition and automated data analysis, the total time-to-result of
AST would be around 60–75 min for 90 % of the analysed
antimicrobials. The flexibility of the software makes adaption
possible to most laboratory information management systems,
even with the integration of movies from each well to ensure
confirmation and acceptance of the test results by clinicians.
The time-to-result for bacterial identification has been short-
ened considerably by the use of mass spectrometry tech-
niques, and, therefore, no longer represents the bottleneck of
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AST. Consequently, the identification of a given infection is
usually available before the results of AST and this informa-
tion can, therefore, be incorporated into the data analysis part
of the software.
Conclusion
Although our data are preliminary, this study suggests that the
oCelloScope system can decrease detection time, making
same-day reporting possible and, thus, permitting better pa-
tient management. With an overall agreement of 96 % for the
nine tested isolates and three positive blood cultures, the rapid
detection time does not interfere with sensitivity. Strains with
methicillin-resistant Staphylococcus aureus (MRSA) and
extended-spectrum β-lactamase (ESBL) resistance profiles
were rapidly detected by the oCelloScope system. A full-
scale validation of the oCelloScope system including more
isolates is necessary to assess the impact of using it for anti-
microbial susceptibility testing (AST).
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